This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ISR Immune System Regulation Holding Valuation

Is ISR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ISR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ISR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ISR's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ISR?

Key metric: As ISR is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ISR. This is calculated by dividing ISR's market cap by their current book value.
What is ISR's PB Ratio?
PB Ratio	-0.6x
Book	-SEK 174.52m
Market Cap	SEK 96.61m

ISR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-1.2x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does ISR's PB Ratio compare to its peers?

The above table shows the PB ratio for ISR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	2.2x
ALZ Alzinova	2.7x	-39.4%	SEK 347.7m
SCOL Scandion Oncology	0.5x	69.7%	SEK 17.7m
ISOFOL Isofol Medical	4.8x	n/a	SEK 434.5m
TOL Toleranzia	0.7x	n/a	SEK 111.1m
ISR ISR Immune System Regulation Holding	n/a	n/a	SEK 96.6m

Price-To-Book vs Peers: ISR is good value based on its Price-To-Book Ratio (-0.6x) compared to the peer average (3.8x).

Price to Book Ratio vs Industry

How does ISR's PB Ratio compare vs other companies in the SE Biotechs Industry?

7 Companies	Price / Book	Estimated Growth	Market Cap
EXPRS2 ExpreS2ion Biotech Holding	0.6x	-11.9%	US$3.58m
SCOL Scandion Oncology	0.5x	69.7%	US$1.61m
DIABIO Diagonal Bio	0.4x	n/a	US$1.05m
CYXO Cyxone	0.3x	n/a	US$886.21k

7 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: ISR is good value based on its Price-To-Book Ratio (-0.6x) compared to the Swedish Biotechs industry average (2.9x)

Price to Book Ratio vs Fair Ratio

What is ISR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ISR PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	-0.6x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ISR's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.